59 completed, 17 terminated, 9 active not recruiting, 6 recruiting. 66 Phase 2, 26 Phase 1, 14 Phase 3, 2 Not applicable, 1 Early Phase 1.
Follow Pemetrexed Disodium: new trials by email Literature Review of Pemetrexed Disodium trials Research Report on Pemetrexed Disodium
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| GFH375 Monotherapy and Combination Therapy as First-Line Treatment for Advanced KRAS G12D-Mutant Non-Small Cell Lung Cancer ArmA:GFH375, Arm B:GFH375, Arm C:GFH375 - NSCLC (Advanced Non-small Cell Lung Cancer) | Phase 2 | Not yet recruiting | Genfleet Therapeutics (Shanghai) Inc. | 90 | 2026-05-20 | 2026-04-28 |
| A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 01(NSCLC)] LBL-024 for Injection, Docetaxel Injection, Bevacizumab Injection - Advanced Solid Tumour | Phase 2 | Recruiting | Nanjing Leads Biolabs Co.,Ltd | 250 | 2025-06-11 | 2026-08-27 |
| Perioperative Tislelizumab for Resectable II-IIIB(N2) KRAS-mutated Nonsquamous Non-small Cell Lung Cancer Tislelizumab, Cisplatin, Carboplatin - Lung Cancer, Non-Small Cell | Phase 2 | Recruiting | Shanghai Chest Hospital | 32 | 2024-11-20 | 2025-05-18 |
| A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors BL-B01D1, PD-1 Monoclonal Antibody, Pemetrexed Disodium - Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma | Phase 2 | Recruiting | Sichuan Baili Pharmaceutical Co., Ltd. | 570 | 2024-06-25 | 2026-07-23 |
| SMET12 and Toripalimab Combined Chemotherapy in Patients With EGFR Positive Advanced Non-small Cell Lung Cancer (NSCLC) SMET12 - EGFR Positive Non-small Cell Lung Cancer | Early Phase 1 | Unknown | Fujian Cancer Hospital | 40 | 2024-01-10 | 2024-01-17 |
| Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma Atezolizumab, Bevacizumab, Biospecimen Collection - Peritoneal Malignant Mesothelioma | Phase 2 | Recruiting | National Cancer Institute (NCI) | 66 | 2022-03-22 | 2026-10-26 |
| Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participants With Metastatic Squamous or Nonsquamous Non-Small Cell Lung Cancer (NSCLC) (MK-3475-A86) Pembrolizumab SC, Pembrolizumab IV, Paclitaxel - Non-Small Cell Lung Cancer | Phase 3 | Completed | Merck Sharp & Dohme LLC | 531 | 2021-08-05 | 2026-10-07 |
| MC200708 Pemetrexed and Pembrolizumab for the Treatment of Recurrent and/or Metastatic Salivary Gland Cancer Pembrolizumab, Pemetrexed Disodium, Biospecimen Collection - Metastatic Salivary Gland Carcinoma, Recurrent Salivary Gland Carcinoma | Phase 2 | Active not recruiting | Mayo Clinic | 45 | 2021-07-23 | 2026-06-04 |
| Camrelizumab Combined With SRT/WBRT and Chemotherapy in Patients With Brain Metastases of Driven Gene-negative NSCLC Camrelizumab, Placebo, Cisplatin - Non-Small-Cell Lung Cancer | Phase 3 | Completed | Guangdong Association of Clinical Trials | 60 | 2021-05-28 | 2026-05-20 |
| Camrelizumab With Chemotherapy in Adults With Medically Inoperable Early Stage NSCLC Biological: Camrelizumab, Pemetrexed, Nab-paclitaxel - Early Stage Non-small Cell Lung Cancer | Phase 2 | Unknown | Tianjin Medical University Cancer Institute and Hospital | 30 | 2020-09-25 | 2020-11-13 |
| Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO]) Biospecimen Collection, Carboplatin, Cisplatin - Lung Non-Small Cell Carcinoma, Lung Non-Small Cell Squamous Carcinoma | Phase 3 | Recruiting | National Cancer Institute (NCI) | 1210 | 2020-06-16 | 2026-10-26 |
| Pembrolizumab With or Without Chemotherapy Before Surgery in Treating Patients With Stage I-IIIA Non-Small Cell Lung Cancer Cisplatin, Pembrolizumab, Pemetrexed - Lung Non-Small Cell Carcinoma, Stage I Lung Cancer AJCC v8 | Phase 2 | Withdrawn | University of California, San Francisco | 2020-05-29 | 2022-03-04 | |
| Comparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in Non-Small Cell Lung Cancer (NSCLC) Tislelizumab, Cisplatin injection, Paclitaxel injection - Non Small Cell Lung Cancer | Phase 3 | Active not recruiting | BeiGene | 453 | 2020-05-29 | 2026-03-18 |
| Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer Carboplatin, Cisplatin, Durvalumab - Recurrent Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8 | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 660 | 2020-04-29 | 2026-10-26 |
| Testing the Addition of Targeted Radiation Therapy to Surgery and the Usual Chemotherapy Treatment (Pemetrexed and Cisplatin [or Carboplatin]) for Stage I-IIIA Malignant Pleural Mesothelioma Carboplatin, Cisplatin, Decortication - Pleural Biphasic Mesothelioma, Pleural Epithelioid Mesothelioma | Phase 3 | Terminated | NRG Oncology | 16 | 2020-01-29 | 2026-07-13 |
| Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Non-Match Treatment Trial) Docetaxel, Gemcitabine, Gemcitabine Hydrochloride - Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8 | Phase 2 | Completed | SWOG Cancer Research Network | 166 | 2019-05-28 | 2024-09-03 |
| Neoadjuvant IBI308, Bevacizumab, Plus Pemetrexed and Carboplatin Followed by Surgery in Unresectable Stage III NSCLC IBI308, Bevacizumab, Pemetrexed - Lung Cancer Stage III | Phase 2 | Recruiting | Sun Yat-sen University | 36 | 2019-03-01 | 2026-04-21 |
| Neoadjuvant JS001, or JS001 in Combination With Pemetrexed and Carboplatin in Resectable NSCLC. JS001, Pemetrexed, Carboplatin - Efficacy and Safety | Phase 2 | Withdrawn | Sun Yat-sen University | 2019-02-01 | 2024-12-06 | |
| Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma Atezolizumab, Cisplatin, Extrapleural Pneumonectomy - Biphasic Mesothelioma, Epithelioid Mesothelioma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 28 | 2018-07-16 | 2026-10-22 |
| Nivolumab Plus Cisplatin/Pemetrexed or Cisplatin/Gemcitabine as Induction in Resectable Non-Small Cell Lung Cancer Nivolumab, Cisplatin, Pemetrexed Disodium - Non-Squamous Non-Small Cell Lung Carcinoma, Stage I Non-Small Cell Lung Cancer | Phase 2 | Terminated | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 14 | 2017-12-20 | 2026-02-20 |
Showing 20 of 103. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (54) · Lung Neoplasms (31) · Adenocarcinoma of Lung (13) · Mesothelioma, Malignant (10) · Adenocarcinoma, Bronchiolo-Alveolar (7) · Solitary Fibrous Tumor, Pleural (4) · Brain Neoplasms (3) · Breast Neoplasms (3) · Head and Neck Neoplasms (3) · Mesothelioma (3) · Ovarian Neoplasms (3) · Carcinoma, Ovarian Epithelial (2) · Fallopian Tube Neoplasms (2) · Lymphoma (2) · Neoplasm Metastasis (2)
National Cancer Institute (NCI) (14) · Alliance for Clinical Trials in Oncology (11) · Gynecologic Oncology Group (5) · Barbara Ann Karmanos Cancer Institute (4) · UNC Lineberger Comprehensive Cancer Center (4) · Vanderbilt-Ingram Cancer Center (4) · Mayo Clinic (3) · SWOG Cancer Research Network (3) · Sun Yat-sen University (3) · University of California, Davis (3) · Wake Forest University Health Sciences (3) · Albert Einstein College of Medicine (2) · Eastern Cooperative Oncology Group (2) · European Organisation for Research and Treatment of Cancer - EORTC (2) · Jonsson Comprehensive Cancer Center (2)
United States (83) · China (13) · Canada (5) · Belgium (3) · France (3) · Guam (3) · Italy (3) · South Africa (3) · United Kingdom (3) · Australia (2) · Israel (2) · Peru (2) · Spain (2) · Sweden (2) · Taiwan (2)
David S. Miller, MD (5) · Alex A. Adjei, MD, PhD (4) · Thomas E. Stinchcombe, MD (3) · Anne S Tsao (2) · Edward Garon (2) · Elizabeth C. Dees, MD (2) · Grace K. Dy, MD (2) · Leora Horn (2) · Shirish Gadgeel (2) · Aaron S Mansfield (1) · Afshin Dowlati, MD (1) · Alex Adjei (1) · Allan Covens, MD (1) · Amelie Lansiaux, MD, PhD (1) · Andreas Rimner, MD (1)
PMID 16135464, PMID 16303865, PMID 16391300, PMID 17442992, PMID 18090584, PMID 18455781, PMID 18459175, PMID 18463792, PMID 19023677, PMID 19494788, PMID 19804902, PMID 19841321, PMID 20209614, PMID 20525721, PMID 20651609, PMID 21282537, PMID 21415776, PMID 21684151, PMID 21747084, PMID 22362813, PMID 22584333, PMID 23420398, PMID 24013936, PMID 24090033, PMID 24099865, PMID 24133369, PMID 24831979, PMID 24985049, PMID 25057165, PMID 25081901, PMID 25881079, PMID 26774201, PMID 26810581, PMID 28489511, PMID 29129443, PMID 30642285, PMID 30702971, PMID 31386610, PMID 32615102, PMID 33608212, PMID 33878954, PMID 35297944, PMID 35379845, PMID 37673112, PMID 39581197, PMID 39929333, PMID 41344593, PMID 41583476, PMID 41666849, PMID 41747891
U10CA180821 (6), P30CA022453 (5), U10CA031946 (4), U10CA180888 (4), U10CA021115 (3), U10CA032102 (3), U10CA180820 (3), U10CA180868 (3), P30CA012197 (2), P30CA013330 (2), P30CA015083 (2), P30CA023074 (2), P30CA043703 (2), P30CA068485 (2), U10CA180830 (2)